Avadel Pharmaceuticals plc Stock price

Equities

AVDL

US05337M1045

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
16.89 USD +0.30% Intraday chart for Avadel Pharmaceuticals plc -1.17% +19.62%
Sales 2024 * 167M Sales 2025 * 301M Capitalization 1.53B
Net income 2024 * -33M Net income 2025 * 91M EV / Sales 2024 * 9.55 x
Net Debt 2024 * 66.33M Net cash position 2025 * 5.71M EV / Sales 2025 * 5.07 x
P/E ratio 2024 *
-37.4 x
P/E ratio 2025 *
21.2 x
Employees 154
Yield 2024 *
-
Yield 2025 *
-
Free-Float 39.35%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.30%
1 week-1.17%
Current month+32.16%
1 month+34.58%
3 months+15.76%
6 months+61.78%
Current year+19.62%
More quotes
1 week
16.20
Extreme 16.2
17.47
1 month
11.82
Extreme 11.82
17.47
Current year
11.82
Extreme 11.82
17.47
1 year
8.00
Extreme 8
17.47
3 years
1.05
Extreme 1.05
17.47
5 years
1.03
Extreme 1.03
17.47
10 years
1.03
Extreme 1.03
26.09
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 17-01-02
Director of Finance/CFO 59 19-12-01
Chief Operating Officer - 14-08-31
Members of the board TitleAgeSince
Director/Board Member 55 18-11-30
Chief Executive Officer 57 17-01-02
Director/Board Member 72 19-12-04
More insiders
Date Price Change Volume
24-03-28 16.89 +0.30% 510,834
24-03-27 16.84 +3.69% 355,913
24-03-26 16.24 -2.11% 463,601
24-03-25 16.59 -3.66% 783,230
24-03-22 17.22 +0.76% 917,945

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
16.89 USD
Average target price
22.9 USD
Spread / Average Target
+35.58%
Consensus
  1. Stock
  2. Equities
  3. Stock Avadel Pharmaceuticals plc - Nasdaq